Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameInnovent Biologics, Inc.
-
Registration countryCayman Islands
-
IndustryMiscellaneous Healthcare: Products and Services
-
М/S&P/F
*** /*** /***









